3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
5
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
18
Hematologic Neoplasms
15
Myelodysplastic Syndromes
14
Leukemia, Lymphocytic, Chronic, B-Cell
9
Multiple Myeloma
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Hodgkin Disease
6
Leukemia
5
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
4
Myeloproliferative Disorders
3
Lymphoma, T-Cell
3
Lymphoma, Large-Cell, Anaplastic
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Turcot syndrome
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Mycosis Fungoides
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Follicular
2
Lymphoma, Extranodal NK-T-Cell
2
Interventions
sargramostim
1
entinostat
1
carboxyamido-triazole
1
bempegaldesleukin
1
Thalidomide
1
Temozolomide
1
Paclitaxel
1
O(6)-benzylguanine
1
Nivolumab
1
Filgrastim
1
Fentanyl
1
Docetaxel
1
Carmustine
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Nivolumab
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts